Nutriband
Develops transdermal drug products centered on its AVERSA abuse-deterrent patch technology.
Something off on this page? Send us feedback.
Profile
Develops transdermal pharmaceutical products through its 4P Therapeutics drug-development business, with AVERSA as the core technology. AVERSA is designed for existing drug patches that can be abused or misused, and AVERSA Fentanyl is the lead program in development.
Develops a portfolio of transdermal pharmaceutical products, with its pipeline principally based on AVERSA, a proprietary abuse-deterrent technology for drug patches that can be abused or misused. The 4P Therapeutics drug-development business became its principal business after the 2018 acquisition, shifting the focus from consumer transdermal products marketed outside the United States. AVERSA Fentanyl is the lead development program.
Founded as Nutriband Ltd. in Ireland, the organization now operates through a Nevada parent headquartered in Orlando, Florida and led by CEO Gareth Sheridan. Common stock has traded on Nasdaq since 2021. AVERSA Fentanyl remains a development-stage product; marketing depends on its development program, including preclinical and clinical trials, and FDA approval.
Company facts
Key statistics
Year to date +0.9% · Average volume (30d) 20.5K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026Q1 FY26 | — | −$0.10 | — | — | $433.4K | — | −3.69% |
| Apr 29, 2026Q4 FY25 | −$1.89 | −$0.04 | +97.9% | $765.0K | $765.0K | 0.0% | +2.11% |
| Dec 16, 2025Q3 FY25 | −$2.13 | −$0.12 | +94.4% | $675.0K | $346.1K | −48.7% | −2.00% |
| Sep 9, 2025Q2 FY25 | −$0.17 | −$2.12 | −1,147.1% | $675.0K | $622.5K | −7.8% | −1.32% |
Financial highlights
| 12 quarters | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $642.4K | $667.4K | $622.5K | $346.1K | $400.7K | $433.4K | |
| Gross profit | $274.6K | $252.0K | $156.9K | $68.5K | $88.9K | $196.8K | |
| Operating income | −$2.0M | −$1.4M | −$2.0M | −$3.9M | −$1.0M | −$1.3M | |
| Net income | −$5.5M | −$1.4M | −$2.0M | −$3.9M | −$968.1K | −$1.2M | |
| Diluted EPS | −$0.51 | −$0.12 | −$2.12 | −$0.32 | −$0.08 | −$0.10 | |
| Gross margin | 42.8% | 37.8% | 25.2% | 19.8% | 22.2% | 45.4% | |
| Operating margin | -305.7% | -211.8% | -321.8% | -1,121.3% | -254.8% | -289.4% |
Fiscal years (4-quarter sums)FY21 $1.4M · FY22 $2.1M · FY23 $2.1M · FY24 $2.1M · FY25 $2.0M
Revenue by geography · Q1 FY26
Balance sheet, Apr 30, 2026Cash & short-term investments $4.0M · Total debt $232.7K · Total assets $6.9M · Shareholders' equity $6.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 12.16M · Float 5.28M · 43.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Vitale Botgros | 4.18M | 32.37% | 13D/A | Sep 19, 2024 |
| Gareth Sheridan · director, 10 percent owner, officer: Chief Executive Officer | 1.76M | 14.49% | Form 4 | Nov 25, 2025 |
| Serguei Melnik | 1.07M | 9.39% | 13D | Mar 13, 2025 |
| Vanguard Capital Management LLC | 174.9K | 1.44% | 13F | May 15, 2026 |
| Geode Capital Management, LLC | 70.1K | 0.58% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Viatris
Marketed generic fentanyl patch for long-term, around-the-clock pain
- Teva (ADR)
Marketed fentanyl patches for continuous 72-hour opioid delivery
- Scilex
Prescription pain topical-system franchise built around ZTlido
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nutriband | $4.46 | −0.22% | $54.2M | — | — | 30.1 | −32.5% |
| Viatris | $16.30 | −0.23% | $19.03B | — | 6.4 | 1.3 | +4.9% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Scilex | $5.43 | −0.18% | $46.1M | — | 58.3 | 1.5 | −22.8% |
| Median | 60.7 | 12.9 | 1.5 | −0.8% |